LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
PHAR
Pharming Group N.V.
There isn't enough reported data to score PHAR yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
PHAR Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Strong |
PHAR's balance sheet is currently strong, but its profitability is under pressure. There isn't enough data to rate its revenue and cash flow.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
PHAR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 17x | N/A | N/A |
| Fair | 35x | N/A | N/A |
| Expensive | 280x | N/A | N/A |
| Current | 324x | $12.95 | — |
Historical ranges are pointers, not guarantees.
PHAR's PE is 324x, but its earnings don't support one, so it isn't a reliable read right now.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over PHAR on the outlook, with more favorable revenue expectations.
PHAR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect PHAR's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the stronger earnings trend. Trailing diluted EPS is up 51% for LLY versus PHAR down 100%.
PHAR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | $0.00 | +$0.02 |
| Q4 2024 | -$0.02 | $0.00 |
| Q4 2023 | -$0.02 | -200% |
| Q4 2022 | $0.02 | 0% |
| Q4 2021 | $0.02 | -60% |
| Q4 2020 | $0.05 | -90% |
| Q4 2019 | $0.51 | +27% |
| Q3 2019 | $0.54 | +$1.17 |
PHAR has swung to a loss: it lost $0.00 per share over the past year, after a profit the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
PHAR has the stronger quarterly revenue trend. Revenue is up 39% for LLY versus up 89% for PHAR.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
PHAR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $376.1M | +27% |
| Q4 2024 | $297.2M | +21% |
| Q4 2023 | $245.3M | +19% |
| Q4 2022 | $205.6M | +3.4% |
| Q4 2021 | $198.9M | -3.6% |
| Q4 2020 | $206.3M | +242% |
| Q4 2019 | $60.4M | +35% |
| Q3 2019 | $51.5M | +2% |
PHAR's revenue has grown year over year for 10 quarters in a row: $376M last quarter, up 89% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | 6.9% | 0 points |
| Q4 2024 | -2.9% | -39 points |
| Q4 2023 | -2.2% | -42 points |
| Q4 2022 | 8.9% | -32 points |
| Q4 2021 | 6.8% | -22 points |
| Q4 2020 | 36% | +1.2 points |
| Q4 2019 | 40% | +21 points |
| Q3 2019 | 40% | +2.5 points |
PHAR's operating margin was 6.9% last quarter, about level with the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with PHAR at down 9.5%.
PHAR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | $54M | +$56.5M |
| Q4 2024 | -$2.6M | +$16.2M |
| Q4 2023 | -$18.7M | -189% |
| Q4 2022 | $21.1M | -22% |
| Q4 2021 | $27.1M | -65% |
| Q4 2020 | $77.6M | +257% |
| Q4 2019 | $21.7M | +21% |
| Q3 2019 | $3.4M | -82% |
PHAR generated $54M in free cash flow over the past year, down 59% from the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over PHAR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
PHAR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -4.9% | -38.5M shares |
| 1 year | +6.5% | +45.7M shares |
| 3 years | +978% | +678M shares |
| 5 years | +1302% | +694M shares |
PHAR has 747M diluted shares, up 6.5% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
| Q3 2019 | — |
| Q2 2019 | — |
| Q1 2019 | — |
| Q4 2018 | — |
| Q3 2018 | — |
| Q2 2018 | — |
| Q1 2018 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
PHAR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2019 | -0.2x | Net Cash |
| Q3 2019 | -0.2x | Net Cash |
| Q2 2019 | 0.1x | Very low |
| Q1 2019 | -0.1x | Net Cash |
| Q4 2018 | 0.1x | Very low |
| Q3 2017 | 4.2x | High |
PHAR has more cash than debt.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
PHAR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.8 | Neutral |
| Stochastic | 79.2 | Neutral |
PHAR's weekly RSI is 55 (neutral) and its Stochastic is 79 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY has the edge over PHAR on valuation relative to its sector.
PHAR PE vs Healthcare Sector
| Metric | PHAR | Sector median | Relative |
|---|---|---|---|
| PE | 324x | 26x | 1,152% above |
| PE % | 93 | 34 | 59 pts above |
PHAR is trading at 324x earnings, a 1152% premium to the Healthcare sector's median of 26x, though its earnings don't support one.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over PHAR on trend strength, trading above more of its moving averages.
PHAR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.0 | 18% above |
| 20 week MA | $11.6 | 12% above |
| 50 week MA | $14.2 | 8.5% below |
| 100 week MA | $12.7 | 1.8% above |
| 200 week MA | $11.7 | 11% above |
PHAR's trend is mixed: it's above four of its five weekly moving averages, and 11% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over PHAR on returns for 2026, with the stronger performance.
PHAR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $15.6 | $15.6 | 0% |
| 2021 | $15.6 | $8.75 | -44% |
| 2022 | $8.75 | $11.8 | +34% |
| 2023 | $11.8 | $11.4 | -2.7% |
| 2024 | $11.4 | $10.2 | -11% |
| 2025 | $10.2 | $17.8 | +74% |
| 2026 YTD | $17.8 | $13.0 | -27% |
PHAR has finished lower in four of the last six years. It's down 27% so far in 2026.